Related Experiment Video
Updated: Oct 5, 2025
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
2.0K
Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update
Pedro Vaz-Salvador1, Rui Adão1, Inês Vasconcelos1
1Department of Surgery and Physiology, Faculty of Medicine, Cardiovascular Research and Development Center - UnIC, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal.
Cardiovascular Drugs and Therapy
|January 31, 2022
Summary
Treatment options for heart failure with preserved ejection fraction (HFpEF) are limited. This review examines recent clinical trials and challenges in developing new pharmacotherapies for HFpEF patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Heart failure with preserved ejection fraction (HFpEF) lacks effective treatments, unlike heart failure with reduced ejection fraction (HFrEF).
- Current HFpEF therapies focus on symptom management and quality of life improvement.
- HFpEF is recognized as a complex syndrome with diverse phenotypes and comorbidities.
Purpose of the Study:
- To review recent Phase III clinical trial outcomes for HFpEF pharmacotherapies.
- To highlight promising drug candidates emerging from Phase II trials.
- To discuss current challenges impeding the development of new HFpEF treatments.
Main Methods:
- Systematic review of recent Phase III clinical trial data for HFpEF.
- Analysis of emerging drug candidates from Phase II HFpEF trials.
- Identification and discussion of barriers in HFpEF drug development.
Main Results:
- Many recent Phase III trials for HFpEF have yielded disappointing results.
- Several drug candidates show promise in earlier-stage trials, warranting further investigation.
- HFpEF heterogeneity complicates trial design and treatment efficacy.
Conclusions:
- Developing effective pharmacotherapies for HFpEF remains a significant clinical challenge.
- Personalized therapeutic approaches may be necessary due to HFpEF complexity.
- Overcoming current developmental hurdles is crucial for advancing HFpEF patient care.
Related Concept Videos
01:30Heart Failure V: Medical Management
39
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
39
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
550
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
550
01:29Heart Failure II: Pathophysiology
91
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
91
01:22Heart Failure VI: Adjunct Therapies
47
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
47
01:26Heart Failure Drugs: Inotropic Agents
782
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
782
01:22Heart Failure Drugs: β-Blockers
460
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
460